Non-invasive in-vivo prediction of therapeutic response to inhibitors of angiogenesis using gallium (68Ga) NODAGA-RGD PET/CT

Primary objectives: 1. To compare the response rate to treatment including antiangiogenic agent in patients with advanced metastatic cancer of the colon or rectum , according to whether or not all known lesions, were visually positive on gallium (68Ga) NODAGA-RGD PET/CT before starting treatment including antiangiogenic agent
Primary endpoints: 1. Assessment of value of gallium (68Ga) NODAGA-RGD PET/CT to predict the response to treatment including antiangiogenic agent